About us

Notash tashkhis Spadana in brief

Notash tashkhis Spadana(NTS) is a globally operating Finish biotechnology company. NTS mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis.NTS  is headquartered in Isfahan, Iran, and has subsidiaries in Tehran and other cities.

Our vision is leading medical diagnosis company in selected following products:

1-Diagnosis kits

2-Laboratory equipments

Notash tashkhis Spadana Group worldwide

NTS employs around 30 people in the country. The company is headquartered in Isfahan, Iran, and has subsidiary in other cities in our territory. Additionally, NTS’s products are sold by distributors in our territory.

NTS´s research and development combines expertise in various fields into integrated know-how. NTS’s personnel together with scientific advisers representing various academic communities apply their knowledge in basic and applied research to develop innovative products for laboratories and the health care industry.

The key personnel are experts in the fields of: 

  •     Medical Laboratory
  •     Medicine
  •     Molecular biology
  •     Biotechnology
  •     Nanotechnology 

This multidisciplinary approach, innovations and application has produced valuable results for the advancement of research and health care all over the world. A further strength of NTS’s multidisciplinary R & D is the ability to react quickly to new customer needs and product ideas.

Notash tashkhis Spadana’s key markets are Asia and middle east NTS  is working to build a committed and focused distributor and partner network and to identify potential new distributors.

New agreements for diagnostic products are being prepared with distributors specializing in gastroenterology. Partners are also being sought for Acetum products, with the objective of establishing co-operation covering sales and marketing, as well as manufacture and regional research in selected areas. Once its products have been registered, NTS helps distributors with, for example, commercialization and user training as required in each country.

Notash tashkhis Spadana’s product range encompasses tests, instruments and analysis systems for laboratories. We also introduced its unique range of Acetium products, which bind carcinogenic acetaldehyde in the stomach.

Primary healthcare forms the main user base for NTS’s gastro Panel examination (for stomach health) and the Colon View quick test (to diagnose the risks of colorectal cancer). Our quick tests for lactose intolerance and H. pyloriare also suitable for use in specialized healthcare. In addition to these tests, the company also markets and sells its own gastro Panel laboratories with varying capacities. They include gastro Panel examination kits, liquid handling equipment, instruments, and software. NTS purchases any liquid handling products required for its diagnostics products and laboratories from Sartorius, which acquired our liquid handling business. The Gastro Panel laboratory concept promotes the effective use of GastroPanel examinations.

The Healthy Stomach Initiative

The Healthy Stomach Initiative’s international research team recommends the use of the gastro Panel examination’s biomarkers for the diagnosis and screening of those suffering from abdominal complaints and asymptomaticH. pyloriinfection, and for atrophic gastritis resulting from H. pylori infection or an autoimmune disease, when it is not safe to use the alternative procedure, the 13C urea breath test. 20–40 % of the population in Western countries suffer from abdominal complaints. Diseases of the gastrointestinal tract are a major source of healthcare costs all across the globe. Many examination and treatment practices are also insufficient and outdated.

New treatment culture, unique solutions

gastro Panel represents the latest in safety, cost-effectiveness, and technological advancement in the field. It doesn’t exhibit any of the serious medical issues as the following tests, which can lead to malpractice and even needless deaths from gastric cancer.

On the basis of the Finnish Setti study (Varis et al., 2000), an estimated 250–300 gastric cancer deaths among the over-50s could be prevented in Finland each year. These deaths could be preventable by using gastro Panel to screen all elderly people for atrophic gastritis, and all suspectedH. pyloripositive patients in particular. Gastroscopy can be conducted on at-risk patients to diagnose early-stage gastric cancers and precancerous lesions while the diseases are still at an asymptomatic and curable stage. In addition to assessing the risk of gastric and esophageal cancer, gastro Panel screening, diagnostics and examinations provide a lot more reliable and valuable information.